{
    "clinical_study": {
        "@rank": "134498", 
        "acronym": "CAMELLIA", 
        "arm_group": [
            {
                "arm_group_label": "Intermittent Capecitabine", 
                "arm_group_type": "Active Comparator", 
                "description": "Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3 week cycle."
            }, 
            {
                "arm_group_label": "Metronomic Capecitabine", 
                "arm_group_type": "Experimental", 
                "description": "Capecitabine 500 mg/m2 three times daily on days 1-21 of each 3-week cycle"
            }
        ], 
        "brief_summary": {
            "textblock": "It is a phase III trial to explore the efficacy and safety of metronomic chemotherapy with\n      Capecitabine versus intermittent Capecitabine as maintenance therapy following first-line\n      Capecitabine plus Docetaxel chemotherapy in treatment of HER2-negative metastatic breast\n      cancer(mBC)."
        }, 
        "brief_title": "Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Neoplasms", 
            "Neoplasms by Site", 
            "Neoplasm Metastasis", 
            "Breast Diseases", 
            "Skin Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Breast Diseases", 
                "Neoplasms", 
                "Neoplasm Metastasis", 
                "Neoplasms by Site", 
                "Skin Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent obtained prior to initiation of any study-specific procedures\n             or treatment as confirmation of the patient's awareness and willingness to comply\n             with the study requirements.\n\n          -  Female patients aged \u2265 18 years.\n\n          -  Histologically confirmed and documented HER2-negative metastatic breast cancer.\n\n          -  Previously untreated first-line chemotherapy.\n\n          -  Patients with at least one measurable lesion according to RECIST criteria at study\n             entry.\n\n          -  Documented ER/PgR status.\n\n          -  Prior hormone therapy for metastatic disease is allowed but must stop before study\n             entry.\n\n          -  KPS>70.\n\n          -  Life expectancy of \u226512 weeks\n\n        Exclusion Criteria:\n\n          -  Previous chemotherapy for metastatic breast cancer.\n\n          -  Prior adjuvant/neoadjuvant chemotherapy within 6 months prior to first study\n             treatment administration.\n\n          -  Prior (radical)radiotherapy for the treatment of metastatic disease or major surgical\n             procedure within 28 days prior to the first study treatment,\n\n          -  Inadequate bone marrow function: absolute neutrophil count (ANC): <1.5 x 109/L,\n             platelet count<75 x 109/L or hemoglobin <100g/L.\n\n          -  Inadequate liver or renal function, defined as:\n\n               1. Serum (total) bilirubin >2 x the upper limit of normal (ULN) for the institution\n\n               2. AST/SGOT or ALT/SGPT >2.5 x ULN (>5 x ULN in patients with liver metastases)\n\n               3. ALP >2.5 x ULN at baseline (>5 x ULN in patients with liver metastases).\n\n               4. Serum creatinine>140umol/L.\n\n          -  Pregnant or lactating females.\n\n          -  Her-2 positive (ICH +++ or FISH positive).\n\n          -  Symptomatic cerebral parenchyma and/or leptomeningeal metastases.\n\n          -  Other malignancy within the last 5 years, except for adequately treated carcinoma in\n             situ of the cervix or squamous carcinoma of the skin, or adequately controlled\n             limited basal cell skin cancer.\n\n          -  Pre-existing peripheral neuropathy \u2265grade 1 according NCI CTCAE 4.0.\n\n          -  Mental disease or other conditions affecting on the compliance of patients.\n\n          -  Other serious disease or medical condition:\n\n               1. History of uncontrolled seizures, CNS disorders or psychiatric disability judged\n                  by the Investigator to be clinically significant precluding informed consent.\n\n               2. Congestive heart failure, or unstable angina, myocardial infarction within \u22646\n                  months prior to the first study treatment, uncontrolled hypertension and high\n                  risk, uncontrolled arrhythmias.\n\n               3. Uncontrolled acute infection\n\n          -  Inability to take or absorption oral medications.\n\n          -  Concurrent or within 30 days using drugs of other clinical trials.\n\n          -  Previous treatments containing Capecitabine (whether adjuvant or palliative\n             treatment).\n\n          -  Previous treatments containing docetaxel within 12 months.\n\n          -  Known hypersensitivity to any of the study treatments or excipients.\n\n          -  Any other conditions the research consider not appropriate to take part in the trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "928", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917279", 
            "org_study_id": "ML28898"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Intermittent Capecitabine", 
                    "Metronomic Capecitabine"
                ], 
                "description": "Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration For the the patients with SD, PR or CR after initiate  treatment phrase will enter into maintenance treatment phase.", 
                "intervention_name": "Docetaxel plus Capecitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Intermittent Capecitabine", 
                "description": "Capecitabine 500 mg/m2 three times daily on days 1-21 of each 3-week cycle", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Xeloda"
            }, 
            {
                "arm_group_label": "Metronomic Capecitabine", 
                "description": "Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3 week cycle", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Xeloda"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Capecitabine", 
                "Antineoplastic Agents", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic Breast Cancer", 
            "Antineoplastic Agents", 
            "Therapeutic Uses", 
            "Antimetabolites", 
            "Tubulin Modulators", 
            "Maintenance chemotherapy", 
            "Metronomic chemotherapy", 
            "Capecitabine", 
            "Docetaxel"
        ], 
        "lastchanged_date": "November 21, 2013", 
        "location": {
            "contact": {
                "email": "xubinghe@medmail.com.cn", 
                "last_name": "Binghe Xu, MD, PhD", 
                "phone": "+86-10-87788826"
            }, 
            "contact_backup": {
                "email": "mafei2011@139.com", 
                "last_name": "Fei Ma, MD", 
                "phone": "+86-13910217780"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100021"
                }, 
                "name": "Cancer Institute and Hospital, Chinese Academy Of Medical Sciences"
            }, 
            "investigator": [
                {
                    "last_name": "Binghe Xu, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Fei Ma, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase III Study of Metronomic vs. Intermittent Capecitabine Maintenance Therapy Following First-line Capecitabine and Docetaxel Therapy in HER2-negative Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "xubinghe@medmail.com.cn", 
            "last_name": "Binghe Xu, MD, PhD", 
            "phone": "+86-10-87788826"
        }, 
        "overall_contact_backup": {
            "email": "mafei2011@139.com", 
            "last_name": "Fei Ma, MD", 
            "phone": "+86-13910217780"
        }, 
        "overall_official": {
            "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", 
            "last_name": "Binghe Xu, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time from randomization to progression or death (whichever occurred first).", 
            "measure": "Progression Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "up to 36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917279"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "Binghe Xu", 
            "investigator_title": "Director of Medical Department", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse events (AEs) and laboratory tests graded according to the NCI CTCAE (version 4.0), premature withdrawals and vital signs. Hand-foot syndrome and diarrhea will be specially interested.\nAdverse events of special interest: hand-foot syndrome and diarrhea. The estimated HFS rate will be about 60% from intermittent Capecitabine vs about 10% from metronomic Capecitabine, diarrhea rate will be about 50% from intermittent Capecitabine vs about 10% from metronomic Capecitabine.", 
                "measure": "Adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 36 months"
            }, 
            {
                "description": "Time from randomization to death", 
                "measure": "Overall survival (OS):", 
                "safety_issue": "No", 
                "time_frame": "up to 52 months"
            }, 
            {
                "description": "Defined as CR+PR, assessed based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria. It will be evaluated in the initial treatment phase and the maintenance treatment phase.", 
                "measure": "Overall Response rates (ORR)", 
                "safety_issue": "No", 
                "time_frame": "up to 36  months"
            }, 
            {
                "description": "Defined as CR+PR+SD, assessed based on on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria. It will be evaluated in the initial treatment phase and the maintenance treatment phase", 
                "measure": "Clinical Benefit rate (CBR)", 
                "safety_issue": "No", 
                "time_frame": "up to 36 months"
            }, 
            {
                "description": "Time from randomization to disease progression", 
                "measure": "Time to Progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "up to 36 months"
            }, 
            {
                "description": "Using the EORTC quality of life questionnaire QLQ-C30", 
                "measure": "QoL", 
                "safety_issue": "No", 
                "time_frame": "up to 36 months"
            }
        ], 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "collaborator": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Binghe Xu", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}